Fiorenzo Simonetti

Medical Doctor, Cardiologist, Ph.D. Fellow
Intravascular Imaging Core Laboratory, ISAResearch Center, German Heart Center Munich, Technical University of Munich

[EuroIntervention @EuroInterventio]

Recurrent TR after T-TEER can limit TTVR when central clips obstruct valve delivery. The ELASTA-T technique enables controlled leaflet detachment to facilitate TTVR.
Read our step-by-step expert review on this novel strategy. #Cardiology

https://t.co/HwbLBYhn19

@FiorenzoSimo @TRheude @StarneckerF @XhepaErion @MichaelJoner3

[EuroIntervention @EuroInterventio]

NEW ISSUE OUT 🔥🔥

- An Expert Review on the ELASTA-T technique for transcatheter tricuspid valve replacement;
- Transcatheter therapies in aortic regurgitation;
- Renal function and antithrombotic therapy in AF-CAD;
- Device depth and flow dynamics in left atrial appendage closure;
- Design and rationale of the NAPT-LAAC trial;
and more

#Cardiology #cardiotwitter

https://t.co/YacVxDFIPu

@MartineGilard
@DIDIERRomain3
@laurenranard
@MichaelJoner3
@dukwoo_park
@freixa_xavier
@FiorenzoSimo
@Albenquegrgoire
@JordiMill

[EuroIntervention @EuroInterventio]

In this study, cangrelor provided effective platelet inhibition during PCI, with low HRPR rates during infusion. Transition to oral P2Y12 inhibitors—particularly clopidogrel—was associated with a transient increase in high residual platelet reactivity. #EIJBestOf
#InterventionalCardiology #Cangrelor #AntiplateletTherapy

🔗https://t.co/a6r2bLSjUe

@GargiuloG83
@espogiov @CirilloPlinio @DSCastiello @IForzano46837 @d_florimonte @FiorenzoSimo @me_canonico @llddss80 @franzone_anna @piccoloraf @vlgmrc

[EuroIntervention @EuroInterventio]

From trial to real-world care
In the Danish registry recently published, @JacobsenRavn et al. showed prasugrel’s advantage over ticagrelor after PCI for MI — confirming ISAR-REACT 5.

@adnan_kastrati & @FiorenzoSimo discuss how real-world evidence closes the loop from RCTs to everyday practice

Editorial: https://t.co/0yudsfereY
Main Paper: https://t.co/KxoNnDO0Zm

[Hemostasis Today @HemostasisToday]

Bleeding Risk: Using DAPT Score to Minimize Complications While Maintaining Efficacy
@piccoloraf | @FiorenzoSimo

https://t.co/hLrSlW0kBH

#BleedingRisk #Cardiology #ClinicalTrial #DAPTScore #Health #Hematology #Hemostasis #PatientCare #HemostasisToday #Medicine #PersonalizedMedicine
#MedED #MedX

[Raffaele Piccolo @piccoloraf]

A personalized DAPT was superior to standard DAPT after PCI.📌Here are the slides presented at: #ESCCongress @mmamas1973 @mirvatalasnag @rwyeh @djc795 @CMichaelGibson @SripalBangalore @Costa_F_8 @pash22 @Ahmed43101178 @Hragy @SABOURETCardio @drjohnm @espogiov @JACCJournals

[Fiorenzo Simonetti @FiorenzoSimo]

Happy to see the presentation of the results of the PARTHENOPE Trial, together with the simultaneous publication in #JACC
https://t.co/wkrN63Sx8Z
This achievement represents years of dedication and strong collective effort.

I’m glad to have been part of this team.
#ESCCongress

[Domenico Angellotti @DomAngellotti]

Are you performing right cath after TTVR?

EJHF: First insights into the impact of TR elimination on right heart:
Immediate RAP reduction ⬇️
Increased systolic RV/PA pressure⬆️ and PAPi ⬆️

Data From Bern by Fabien Praz

🔗 https://t.co/W0gxh7CxyR

@EJHFEiC #CardioTwitter

[Fiorenzo Simonetti @FiorenzoSimo]

Can OCT guide treatment for in-stent restenosis?
While essential in complex PCI, its role in this setting remains unclear.
The ISAR-DESIRE 5 randomized trial will provide new evidence. #OCT #ISR #Intravascularimaging #interventionalcardiology

https://t.co/48lnlvgVCZ

[EuroIntervention @EuroInterventio]

The PARTHENOPE trial addresses the ongoing challenge of balancing restenosis, stent thrombosis, and bleeding in coronary interventions. Decades of advancements point to the need for personalized strategies in antiplatelet therapy. Read the editorial: https://t.co/GrU751FeVD

[EuroIntervention @EuroInterventio]

The PARTHENOPE trial showed that polymer-free amphilimus-eluting stents (AES) are non-inferior to biodegradable-polymer everolimus-eluting stents (EES) for PCI outcomes at 1 year. AES outcomes were comparable overall, with results adding to evidence on DES options. Full details: https://t.co/WktHcSg0sG #Cardiology #PCI #EAPCI
@piccoloraf

[Raffaele Piccolo @piccoloraf]

Our randomized trial found similar platelet inhibition with ticagrelor 60 vs. 90 mg in elderly patients undergoing PCI during the early phase of ACS

#CardioTwitter @escardio @TCTMD @PCRonline @SCAI @MattiaGalli10 @FeliceGragnano @EditorEHJCVP @UninaIT

https://t.co/Lg3aQFJ1I3

[Domenico Angellotti @DomAngellotti]

@piccoloraf Mortality risk was increased in patients with 4th UDMI periprocedural MI fulfilling 2 or 3 criteria, but not in those meeting 1 criterion. These findings may suggest a need to refine the fourth UDMI periprocedural MI definition.

https://t.co/HcdZfpeTZn

[JPM_MDPI @JPM_MDPI]

📢Check out today's #Highly_Cited Paper
"Ultrathin Struts Drug-Eluting Stents: A State-of-the-Art Review"

👨‍🔬 Attilio Leone et al.
🏫University of Naples Federico II @UninaIT
👍 Article Views 4255; Citations 8
🍀https://t.co/qqFI3GzISA
@MDPIOpenAccess @MediPharma_MDPI

[Giuseppe Gargiulo @GargiuloG83]

Pharmacodynamic effects of cangrelor in elective complex PCI: insights from the POMPEII Registry via @EuroInterventio https://t.co/mK3ov2qigp proud of this! Cangrelor as effective and safe option for COMPLEX PCI but attention to transition to oral P2Y12i...

[Raffaele Piccolo @piccoloraf]

@SABOURETCardio Thank you so much to everyone who is interested in this paper! Using hs-cTnI vs. CK-MB, we found highly different rates of SCAI periprocedural MI (13% vs. 2%). There are little clinical consequences for hs-cTnI SCAI periprocedural MI in the absence of CK-MB criteria.